EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Urinary Metabolomic Profiles of Bladder and Prostate Cancer by LC-HRMS: A Comparative Study

Anastasiia Frolova, Yury Ikhalaynen, Mikhail Vokuev, Andrey Stavrianidi, Igor Rodin

Analytica · 18.11.2026 · 7 (4) · 101

DOI: 10.3390/analytica7040101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytica, online erschienen am 18.11.2026. Verfasst von Anastasiia Frolova und 4 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Urinary LC-HRMS metabolomics non-invasively reflects cancer-associated biochemical alterations. However, candidate panels are rarely re-tested in new cohorts or checked against confounding factors, and comparative studies between cancers must differentiate shared from disease-specific changes. We applied a sample preparation and LC-HRMS workflow, previously optimized by design of experiments, to a new cohort of 94 participants (29 bladder cancer, BC; 20 prostate cancer, PC; 45 controls). Data processing combined QC-based filtering, grouping of ions into compounds, exclusion of exogenous signals, adjusted models, matched pairs and cross-validation with permutation testing. After quality filtering, 7403 of 14,693 features were retained (median QC RSD 8.6%). Adjusted for age, sex and exogenous signals, 188 compounds differed between BC and controls. Five were tentatively annotated (MSI levels 2–3): glucuronides of 11-oxoetiocholanolone and tetrahydrocortisone (two isomers), Lysophosphatidylcholine (LysoPC(16:0)) and biliverdin, where 11-oxoetiocholanolone glucuronide was the main candidate. Cross-validated classification of BC gave AUC 0.81 in all samples and 0.68 in matched pairs; these internal estimates require independent validation. An apparent BC-PC separation (AUC 0.86) was not significant after adjustment for exogenous signals, and no PC-specific compounds were found. Controlling for exogenous and demographic factors during data processing gives conservative estimates of urinary metabolomic differences and helps to prevent false-positive findings.

Förderung

  • Ministry of Science and Higher Education of the Russian Federation

Zitieren

APA

Frolova, A., Ikhalaynen, Y., Vokuev, M., Stavrianidi, A., & Rodin, I. (2026). Urinary Metabolomic Profiles of Bladder and Prostate Cancer by LC-HRMS: A Comparative Study. Analytica, 7(4), 101. https://doi.org/10.3390/analytica7040101

Vancouver

Frolova A, Ikhalaynen Y, Vokuev M, Stavrianidi A, Rodin I. Urinary Metabolomic Profiles of Bladder and Prostate Cancer by LC-HRMS: A Comparative Study. Analytica. 2026;7(4):101. doi:10.3390/analytica7040101

BibTeX
@article{Frolova2026,
  author = {Frolova, Anastasiia and Ikhalaynen, Yury and Vokuev, Mikhail and Stavrianidi, Andrey and Rodin, Igor},
  title = {Urinary Metabolomic Profiles of Bladder and Prostate Cancer by LC-HRMS: A Comparative Study},
  journal = {Analytica},
  year = {2026},
  volume = {7},
  number = {4},
  pages = {101},
  doi = {10.3390/analytica7040101}
}
Kostenlos starten →